GT BIOPHARMA, INC. Litigation Settlement, Expense
GT BIOPHARMA, INC. (GTBP) reported Litigation Settlement, Expense of $425.00 thousand for the 0-month period ending 2022-03-04, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2023-03-30
- GT BIOPHARMA, INC. litigation settlement, expense for the quarter ending 2021-09-30 was $0.00.
- GT BIOPHARMA, INC. litigation settlement, expense for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. litigation settlement, expense for the quarter ending 2020-09-30 was $0.00.
- GT BIOPHARMA, INC. litigation settlement, expense for the quarter ending 2020-06-30 was $11.21M.
| Period end | Litigation Settlement, Expense 0 month | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 3 month as first filed | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 6 month as first filed | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 9 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-03-04 | $425.00K 10-K · filed 2023-03-30 | ||||||
| 2022-02-07 | $425.00K 10-Q · filed 2022-08-15 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-12-29 | $0.00 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $0.00 10-Q/A · filed 2021-12-29 | $0.00 10-Q/A · filed 2021-12-29 | |||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $11.21M derived: sum of 2 quarters · filed 2021-12-29 | $11.21M 10-Q · filed 2021-11-10 | $2.56M 10-Q · filed 2020-11-13 | |||
| 2020-06-30 | $11.21M 10-Q/A · filed 2021-12-29 | $2.56M 10-Q · filed 2020-08-14 | $11.21M 10-Q/A · filed 2021-12-29 | $2.56M 10-Q · filed 2020-08-14 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-13 | $0.00 derived: sum of 2 quarters · filed 2020-11-13 | $0.00 10-Q · filed 2020-11-13 | ||||
| 2019-06-30 | $0.00 10-Q/A · filed 2020-08-18 | $0.00 10-Q/A · filed 2020-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |